Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GunnerGon Feb 19, 2020 9:05pm
61 Views
Post# 30710929

RE:again gunner and gobb post together/same genius

RE:again gunner and gobb post together/same geniusRealstups, I have no Idea what you were trying to express with your post.  Try english and sentences.  I have Gobbs on ignore so thanks for keeping me informed on his posts.

Also, this is from the Feb 2020 corporate presentation.  Notice "Anticipated Ryplazim" approval is now 2021.

APPROVAL REALSTUPS, APPROVAL.  Not talking submission of BLA.


 Anticipated Milestones: 2021 & beyond 

Anticipated RyplazimTM FDA approval and launch 

Topline data from fezagepras Phase 2 studies in respiratory disease 

Topline data from fezagepras Phase 3 study in ALSM 

Advancement of early-stage R&D programs 

 
<< Previous
Bullboard Posts
Next >>